/
Through the advancement of our technology platform, we are reimagining how medicines are made to transform how we treat and prevent diseases. Since our founding, our mRNA platform has enabled the development of vaccine and therapeutic candidates across infectious disease, oncology, rare disease and more.
$47.26
$0.86 (-1.79%)
Price from 13 days ago
The business is unprofitable at the operating level (-158.13% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue declined 39.9% YoY. Margins deteriorated 36.2pp alongside, both lines moving the wrong way.
Negative free cash flow of -$2.06B. The business is consuming cash, not generating it. Operating margin contracted 36.2pp YoY, cost discipline may be slipping.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$2.23B
▼ -39.9% YoY
Net Income (TTM)
-$3.19B
▲ +20.8% YoY
Op. Margin
-153.35%
▼ -36.2pp YoY
ROIC
-27.74%
▲ +0.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$1.60B
▲ +49.1% YoY
Op. Cash Flow (TTM)
-$1.47B
▲ +37.6% YoY
Net Debt
-$3.91B
Net Cash Position
Cash & Equiv.
$5.21B
5Y CAGR: +19.3%
Continue Research